Novo Nordisk A/S (NVO)
NYSE: NVO · Real-Time Price · USD
41.17
-0.03 (-0.07%)
At close: Apr 28, 2026, 4:00 PM EDT
41.23
+0.06 (0.15%)
After-hours: Apr 28, 2026, 7:58 PM EDT
Novo Nordisk Employees
As of December 31, 2025, Novo Nordisk had 69,505 total employees, including 76,302 full-time and 1,047 part-time employees. The number of employees decreased by 7,844 or -10.14% compared to the previous year.
Employees
69,505
Change (1Y)
-7,844
Growth (1Y)
-10.14%
Revenue / Employee
$699,061
Profits / Employee
$231,692
Market Cap
184.25B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 69,505 | -7,844 | -10.14% |
| Dec 31, 2024 | 77,349 | 13,030 | 20.26% |
| Dec 31, 2023 | 64,319 | 9,134 | 16.55% |
| Dec 31, 2022 | 55,185 | 6,707 | 13.84% |
| Dec 31, 2021 | 48,478 | 3,155 | 6.96% |
| Dec 31, 2020 | 45,323 | 2,065 | 4.77% |
| Dec 31, 2019 | 43,258 | 56 | 0.13% |
| Dec 31, 2018 | 43,202 | 520 | 1.22% |
| Dec 31, 2017 | 42,682 | 711 | 1.69% |
| Dec 31, 2016 | 41,971 | 1,333 | 3.28% |
| Dec 31, 2015 | 40,638 | -319 | -0.78% |
| Dec 31, 2014 | 40,957 | 2,521 | 6.56% |
| Dec 31, 2013 | 38,436 | 3,705 | 10.67% |
| Dec 31, 2012 | 34,731 | 2,099 | 6.43% |
| Dec 31, 2011 | 32,632 | 2,149 | 7.05% |
| Dec 31, 2010 | 30,483 | 1,154 | 3.93% |
| Dec 31, 2009 | 29,329 | 2,754 | 10.36% |
| Dec 31, 2008 | 26,575 | 1,059 | 4.15% |
| Dec 31, 2007 | 25,516 | 1,903 | 8.06% |
| Dec 31, 2006 | 23,613 | 1,153 | 5.13% |
| Dec 31, 2005 | 22,460 | 1,735 | 8.37% |
| Dec 31, 2004 | 20,725 | 1,969 | 10.50% |
| Dec 31, 2003 | 18,756 | 751 | 4.17% |
| Dec 31, 2002 | 18,005 | 1,864 | 11.55% |
| Dec 31, 2001 | 16,141 | 2,389 | 17.37% |
| Dec 31, 2000 | 13,752 | 1,758 | 14.66% |
| Dec 31, 1999 | 11,994 | 345 | 2.96% |
| Dec 31, 1998 | 11,649 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| Johnson & Johnson | 138,200 |
| AstraZeneca | 95,100 |
| Novartis AG | 75,267 |
| Pfizer | 75,000 |
| Merck & Co. | 75,000 |
| Sanofi | 74,846 |
| GSK plc | 66,841 |
| AbbVie | 57,000 |
NVO News
- 6 hours ago - Health Canada approves first generic version of Novo Nordisk's Ozempic - Reuters
- 15 hours ago - Novo Nordisk to present new data on Wegovy®, women with obesity and next-generation weight loss treatments at European Congress on Obesity - GlobeNewsWire
- 21 hours ago - Boehringer-Zealand drug leads to 16.6% weight loss in late-stage trial - Reuters
- 1 day ago - Novo Nordisk A/S - share repurchase programme - GlobeNewsWire
- 4 days ago - Is It Too Late to Buy Novo Nordisk AS (NVO) After 6.9% Rally? GF Value Says Undervalued - GuruFocus
- 4 days ago - Lilly stock falls as Foundayo trails Novo's Wegovy in early uptake - Invezz
- 4 days ago - Battle Of The Weight-Loss Pills Continues With A Shocking Twist - Investor's Business Daily
- 4 days ago - Novo Nordisk Shares Rise After Positive Oral Semaglutide Trial In Children - Benzinga